These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18708833)

  • 1. Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks.
    Wilson J
    Gastroenterol Nurs; 2008; 31(4):286-92. PubMed ID: 18708833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L; Wilson L
    Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.
    Cohen RD
    Aliment Pharmacol Ther; 2006 Aug; 24(3):465-74. PubMed ID: 16886912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
    Olmstead J
    J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
    Ng SC; Kamm MA
    Aliment Pharmacol Ther; 2008 Oct; 28(7):815-29. PubMed ID: 18627362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A; Spinella S; Levenstein S; Prantera C
    Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T; Probert CS; Keshav S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulcerative colitis: current medical therapy and strategies for improving medication adherence.
    Zhang Z; Kennedy H
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):1-8. PubMed ID: 19011573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcerative colitis therapy: importance of delivery mechanisms.
    Rochester J; Abreu MT
    Rev Gastroenterol Disord; 2005; 5(4):215-22. PubMed ID: 16369217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.
    Bernick SJ; Kane S
    Expert Rev Clin Immunol; 2010 Jul; 6(4):677-82. PubMed ID: 20594140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New lessons: classic treatments, expanding options in ulcerative colitis.
    Hanauer SB
    Colorectal Dis; 2006 May; 8 Suppl 1():20-4. PubMed ID: 16594960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which oral aminosalicylate for ulcerative colitis?
    Drug Ther Bull; 2011 Jan; 49(1):8-12. PubMed ID: 21220254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis.
    Tindall WN
    Am J Health Syst Pharm; 2009 Mar; 66(5):451-7. PubMed ID: 19233992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
    Klotz U
    Dig Liver Dis; 2005 Jun; 37(6):381-8. PubMed ID: 15893274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ
    J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
    Lichtenstein GR; Kamm MA
    Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.